No, the CSL product line is too high end and hard to replicate , generic manufacturers selling in the US might have a problem though . But the buying opportunity comes from what the market today will think of Trump's tirade against pharma.
No, the CSL product line is too high end and hard to replicate ,...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$301.81 |
Change
-4.220(1.38%) |
Mkt cap ! $145.8B | |||
| Open | High | Low | Value | Volume |
| $302.89 | $302.89 | $299.73 | $34.79M | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28 | $301.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $301.88 | 7 | 2 |
View Market Depth
| Last trade - 11.50am 04/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |